Wiley, Hepatology, 3(64), p. 774-784, 2016
DOI: 10.1002/hep.28600
Export citation
Search in Google Scholar
Show less
Full text: Unavailable
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma